| Target Professions: | DO, MD, Nurse Practitioner, Physician Associate/Assistant |
| Target Specialties: | Dermatology, Oncology, Plastic Surgery |
| Credits Available: | 6.0 hours of AMA PRA Category 1 Credit™, MOC Points Available |
Non-melanoma skin cancers (NMSC) represent a class of heterogeneous cutaneous malignancies including basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), Merkel cell carcinoma (MCC), and rarer skin cancers. Accounting for one third of all cancer diagnoses, NMSCs are the most diagnosed malignancies in the world. It is estimated that 5 million BCCs and 1 million cases of SCC are diagnosed every year in the United States. Of these, high-risk SCC and BCC are relatively rare, while MCC, by its nature, is always considered high risk. Despite their relative rarity, high-risk NMSCs have a disproportionate impact on patient outcomes. The Gather-ed small group social learning platform will provide participating clinicians within each group with the opportunity, over a six-week period, to complete foundational materials asynchronously, and to engage with their colleagues and peers involved in the management of high-risk NMSC through live Group Leader-led synchronous interactions focused on areas of greatest concern of the group members, with peer-to-peer exchanges further encouraged in group case-based challenges.
Answer the questions to gauge your current knowledge of high-risk NMSC: risk stratification, immunotherapy/trial referral, care of immunosuppressed patients, irAE management, and multidisciplinary coordination.
This module explores how to identify and manage high-risk non-melanoma skin cancers (NMSC), with a focus on cutaneous squamous cell carcinoma (cSCC).
This module explores the rapidly evolving role of immunotherapy in non-melanoma skin cancers, with an emphasis on cutaneous squamous cell carcinoma (cSCC).
This module explores the unique challenges of managing non-melanoma skin cancers in immunocompromised patients, particularly organ transplant recipients.
This module explores how clinicians can identify and manage immune-related adverse events in patients with non-melanoma skin cancers receiving systemic therapy.
After completing the modules, answer these questions to assess your mastery of high-risk NMSC: stratification, immunotherapy/trial referral, care of immunosuppressed patients, irAE management, and multidisciplinary coordination.
During this discussion, we will review the modules and approaches to treatment that offer optimal care to patients with NMSC.
A 68-year-old man, 8 years post–renal transplant, presents with a rapidly growing 2.5-cm scalp nodule. Debulk pathology: poorly differentiated cSCC with 0.18-mm PNI. Plan work-up, definitive therapy, and adjuvant strategy.
Considering the information reviewed and discussed during this program, please share an action plan that you will implement to improve the diagnosis and management for your patients with NMSC.
During this session, we will review the self-study modules, review the patient case and discuss treatment plans. We will share our action plans and discuss how this CME activity will shape our practice regarding patient care.
